March 12, 2018 / 10:18 AM / 2 months ago

BRIEF-Ritter Pharmaceuticals Reports Microbiome Data From Phase 2B Study Of RP-G28 Promotes Beneficial Adaptation Of The Gut Microbiome

March 12 (Reuters) - Ritter Pharmaceuticals Inc:

* RITTER PHARMACEUTICALS REPORTS MICROBIOME DATA FROM PHASE 2B STUDY OF RP-G28 PROMOTES BENEFICIAL ADAPTATION OF THE GUT MICROBIOME

* RITTER PHARMACEUTICALS INC - ‍DURING PHASE 2A STUDY, OBSERVED AN INCREASE IN BIFIDOBACTERIA, WHICH WERE CONFIRMED IN LARGER PHASE 2B STUDY​

* RITTER PHARMACEUTICALS INC - ‍PHASE 3 CLINICAL TRIAL OF RP-G28 FOR TREATMENT OF LACTOSE INTOLERANCE IN Q2 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below